Synthego Corporation

hfCas12Max’s compact size is revolutionizing the way we approach ex vivo and in vivo CRISPR-based therapeutics. ✅ hfCas12Max nuclease is small in size compared to larger nucleases like SpCas9 ✅ hfCas12Max can be complexed with crRNA without the need for a tracrRNA, meaning its gRNA is smaller, too.  ✅ hfCas12Max nuclease and gRNA can be packaged in LNPs and AAVs Start developing your #CRISPR -based therapeutic using hfCas12Max today! 🔗 👉 https://lnkd.in/g8Wv_bTd

After a nice holiday weekend, we would like you to join us in welcoming several new #Synthegoats to the herd! Our new additions include Stephanie Adamany as our new Chief Legal Officer, James Gangwish as a Senior Strategic Account Manager for our West Coast territories, and Mark Shustock as a Senior Manager of Technical Accounting & Financial Reporting. We also have Neeshia Cabanban who is rejoining us as a Lead Laboratory Associate in our Pre-Clinical Production team. We are excited to see all that they accomplish with us!

Happy Fourth of July From the Synthego Team! While there's a lot of chemistry involved in creating the vibrant colors of fireworks, we wish you a safe and enjoyable Independence Day. 🎆 🎇 Celebrate responsibly, and enjoy the festivities!

In the realm of developing CRISPR-based cell and gene therapies, minimizing off-target editing is paramount. Traditional nucleases can produce undesirable off-target edits, potentially jeopardizing the success of your CRISPR-based cell and gene therapy. Experience minimized off-target editing with hfCas12Max comparable to other Cas12a nucleases, enabling you to focus on the critical downstream assays essential for developing your #CRISPR -based cell and gene therapy. 🧬 See more hfCas12Max off-target analysis data via the link in the comments! 🤓

Help us celebrate these #Synthegoats who Knocked Out another year with us in June! Congratulations on your work anniversaries. Valerie Garcia, Andrea E., Andy L.,Minh La, Ruby Fernandez-De Casas, PhD, James Zaininger, Sinchana Lokesha, Ryan Lu, Romina Iranmanesh, Carlos Cervantez, Yusuf Smith

We recently launched hfCas12Max nuclease and showcased its clinical potential in a recent joint webinar with HuidaGene Therapeutics , which you can now access on demand. 🖥️ 👀 Learn what sets hfCas12Max apart from other #crispr nucleases, and how hfCas12Max is integrated into our RUO-to-GMP continuum to support the development of CRISPR-based cell and gene therapies. 🧬 Watch Now: https://lnkd.in/grXi9S_C

The “hf” in hfCas12Max stands for high-fidelity, and it’s not just a label—it's fact. hfCas12Max surpasses other common CRISPR nucleases by delivering high on-target editing with minimized off-target editing, which is critical for developing precise and effective #crispr -based cell and gene therapies. See for yourself how hfCas12Max is the right nuclease for you: https://lnkd.in/g7FjR7Gf

Test out hfCas12Max nuclease yourself with our validated gRNA! 🧬 Access the target sequences via the link in the comments. 👇 Place your order in our user-friendly order interface. 🛒 We synthesize your high-quality gRNA fast. ⚡️ Achieve your highest editing efficiencies using hfCas12Max where other nucleases may not! #crispr

While Cas9 dominates in #CRISPR applications, its limitations—such as off-target editing and size pose challenges—are noteworthy. Overcome these limitations by exploring alternative nuclease variants to find the right one for your experimental and therapeutic development needs. Check out our guide to discover which variant is right for you. 🧬 🔗👉 https://lnkd.in/gpfVV8Bv

A day to remember, rejoice, and renew our commitment to a world where freedom and equality aren’t just ideas, but realities for all. Let’s raise our beakers to progress, understanding, and the endless pursuit of knowledge that unites us. #Juneteenth